SHC
Sotera Health Company · Healthcare · Medical - Diagnostics & Research
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q2 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 93 | -4 | 114.64M | $2.03B | +6 | −9 |
| Q1 2026 | 99 | +7 | 101.03M | $1.45B | +12 | −6 |
| Q4 2025 | 93 | +4 | 88.33M | $1.56B | +5 | — |
| Q3 2025 | 15 | -1 | 46.41M | $729.96M | — | −2 |
| Q2 2025 | 14 | +1 | 41.75M | $464.28M | +2 | −1 |
| Q1 2025 | 10 | +3 | 12.24M | $142.70M | +3 | — |
| Q4 2024 | 7 | -3 | 12.67M | $173.20M | — | −3 |
| Q3 2024 | 9 | -1 | 11.24M | $187.78M | +1 | −2 |
| Q2 2024 | 10 | — | 8.23M | $97.70M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Millennium Management ✦ | 2.86M | — | $33.90M | 0.0% | n/c | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 2.31M | — | $27.41M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | Geode Capital Management ✦ (passive) | 2.31M | — | $27.41M | 0.0% | n/c | 1 | SEC ↗ |
| 4 | Norges Bank ✦ (passive) | 1.22M | — | $14.45M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Citadel Advisors ✦ | 667.87K | — | $7.93M | 0.0% | n/c | 1 | SEC ↗ |
| 6 | Citadel Advisors ✦ | 667.87K | — | $7.93M | 0.0% | n/c | 1 | SEC ↗ |
| 7 | AQR Capital Management ✦ | 511.58K | — | $6.07M | 0.0% | n/c | 1 | SEC ↗ |
| 8 | AQR Capital Management ✦ | 511.58K | — | $6.07M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 511.58K | — | $6.07M | 0.0% | n/c | 1 | SEC ↗ |
| 10 | Greenlight Capital (DME Capital) ✦ | 300.11K | — | $3.56M | 0.2% | n/c | 1 | SEC ↗ |
| 11 | Greenlight Capital (DME Capital) ✦ | 300.11K | — | $3.56M | 0.2% | n/c | 1 | SEC ↗ |
| 12 | Gotham Asset Management ✦ | 200.43K | — | $2.38M | 0.0% | n/c | 1 | SEC ↗ |
| 13 | Point72 Asset Management ✦ | 74.40K | — | $883,163 | 0.0% | n/c | 1 | SEC ↗ |
| 14 | T. Rowe Price ✦ | 62.05K | — | $737,000 | 0.0% | n/c | 1 | SEC ↗ |
| 15 | Marshall Wace ✦ | 32.70K | — | $388,101 | 0.0% | n/c | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 293 holders, 275.22M shares, $3.76B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 294.51K sh · $5.45M
Officer, Director · 850.00K sh · $15.73M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology